Created by AdvA studio

Innoventions ltd. © 2018 | Israel ישראל | info@innovention-med.com

logo Innoventions

The Incubator for Medical Devices

  • LinkedIn Social Icon

TDNS
Novel Wearable Electrostimulator for Overactive Bladder

Field:

Urology, Uro-Gynecology, Gerontology, Pediatric

Description:

The popularity of wearable devices already have a significant impact on personal healthcare. Sensors and electrodes integrated in wearables are changing the way in which patients are viewing their wellbeing and healthcare. Wearable devices are becoming the truly game-changing possibilities in modern healthcare-giving. Innoventions developed a wearable treatment alternative to peripheral  Percutaneous or Transcutaneous devices for Sacral Plexus Stimulation for the treatment of Over Active Bladder (OAB), OAB related  Nocturnal Enuresis (bed wetting) and Nocturia. Our device takes into consideration the aspect of the wearable that fits the patient’s lifestyle.

 

Need:

According Urology Care Foundation of the American Urological Association “About 33 million Americans have overactive bladder. As many as 30% of them are men and 40% are women living with OAB symptoms. Most probably the real number of people living with OAB is much larger. That's because they do not ask for help thinking that there are not any treatments for their problem.“ (urologyhealth.org)

The market research organization Technavio’s online survey found that “around 12% of these individuals are compelled to stay at home, 23% of women witnessed weight gain, and 38% of women experienced a decrease in their physical activities. OAB in women also results in disturbed sleep, decreased self-esteem, decreased libido, and low mood. This in turn, leads to several psychological conditions, particularly depression and anxiety.”  (www.technavio.com)

Advantages:

  • A novel approach for reducing OAB symptoms

  • Wearable device – Can be worn anywhere and anytime

  • No need for repeated office based treatments

  • Non-invasive - No needle insertion for stimulating the nerves

  • No bladder training exercises

  • Minimal need for patient cooperation

  • Stimulation sessions during daily activities

  • Discreet – Patient friendly

  • Very low electrical stimulation

  • Painless

  • Users will get the most of their walk

  • Possibility of data collection related to bladder activity

  • Bluetooth connectivity

  • Affordable

  • Direct to consumer market

  • 510(k) or Class I device – similar to TENS devices
     

R&D status:

First Generation units were built for pilot study evaluation

 

IP status:

PCT/IL2016/050922

Business opportunity:

Urine incontinence provides a lucrative market opportunity and currently holds the largest market share due to factors such as increasing number of aging population suffering from urine incontinence, rising number of prostate gland related diseases. Fecal incontinence promises a very good sales forecast for the period 2017-2025 majorly due to factors such as rising prevalence and increasing number of patients with ulcerative colitis resulting in altered bowel peristaltic activity leading to leakage of feaces.

The global neuromodulation devices market was valued at US$3.155 bn in 2012 and is anticipated to rise to US$7.072 bn in 2018, progressing at a CAGR of 14.4% from 2013 to 2018. In terms of geography, North America was the leading segment by revenue in 2013 and is anticipated to lead the market by the end of 2018 with a dominant share of 60% in the global neuromodulation devices market.

The latest market report published by Credence Research, Inc. “Sacral Nerve Stimulation Market – Growth, Future Prospects, Competitive Analysis, 2017 – 2025,” the global sacral nerve stimulation market was valued at US$ 2,027.8 Mn in 2016, and is expected to reach US$ 3,145.8 Mn by 2025 expanding at a CAGR of 4.94 % from 2017 to 2025.